Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy.
1/5 보강
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an emerging target in cancer immunotherapy, recognized for its consistent and elevated expression across several epithelial tumors, including
APA
Wong JKM, Lam PY, et al. (2026). Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy.. Molecular therapy : the journal of the American Society of Gene Therapy, 34(3), 1382-1398. https://doi.org/10.1016/j.ymthe.2025.11.021
MLA
Wong JKM, et al.. "Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy.." Molecular therapy : the journal of the American Society of Gene Therapy, vol. 34, no. 3, 2026, pp. 1382-1398.
PMID
41338184 ↗
Abstract 한글 요약
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an emerging target in cancer immunotherapy, recognized for its consistent and elevated expression across several epithelial tumors, including triple-negative breast cancer (TNBC). TNBC is an aggressive and difficult-to-treat cancer, with limited effective therapeutic options currently available. Therapeutic approaches centered on targeting ROR1 have therefore become increasingly popular, with ROR1 chimeric antigen receptor (CAR) T cells currently in clinical trials to treat TNBC patients. While ROR1-targeting therapies have shown promising preclinical results, single arm treatment has often shown low efficacy as well as off-target toxicity. Natural killer (NK) cell-based immunotherapies, such as antibody-dependent cell cytotoxicity-inducing monoclonal antibodies and CAR NK cells, have also been shown to induce cancer cell cytotoxicity; however, with less toxicity compared with CAR T cells. Here, we developed and characterized a phage-derived single-chain fragment variable (scFv) against a highly specific ROR1 region and generated scFv-derived chimeric monoclonal antibodies and anti-ROR1-CAR NK cells, which show anti-cancer efficacy against TNBC cells. Additionally, we found TGF-β inhibition using either small-molecule inhibitors or CRISPR-Cas9-edited NK cells could further enhance ROR1-targeting therapy persistence and efficacy in controlling TNBC tumor growth.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Receptor Tyrosine Kinase-like Orphan Receptors
- Humans
- Animals
- Mice
- Cell Line
- Tumor
- Triple Negative Breast Neoplasms
- Immunotherapy
- Killer Cells
- Natural
- Xenograft Model Antitumor Assays
- Receptors
- Chimeric Antigen
- Female
- Single-Chain Antibodies
- Adoptive
- ADCC
- CAR NK cells
- CRISPR/Cas9
- Frizzled-Kringle domain
- TGFBR2 knockout
- antibody drug conjugate
- natural killer cells
- phage display
… 외 2개
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.